Drugs / HOV12020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04658823 | Dec 2020 → Feb 2024 | cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 | Hovid Berhad | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HOV12020 | “We evaluated the efficacy and safety of a tocotrienol-rich vitamin E complex (HOV12020) in patients with CADASIL.” PMID 42005919 ↗ Mar 2026 |
| Route | Oral | “Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily” NCT04658823 ↗ |